Administration of palmitoylethanolamide in combination with topiramate in the preventive treatment of nummular headache

Chirchiglia, Domenico; Torre, Attilio Della; Signorelli, Francesco; Volpentesta, Giorgio; Guzzi, Giusy; Stroscio, Carmelino Angelo; Deodato, Federica; Gabriele, Donatella; Lavano, Angelo

doi:10.2147/imcrj.s106323

Cited by 14 publications

(11 citation statements)

References 12 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous case series, Hesselink ( 28 ) documented that the administration of PEA 1,200 mg/day in patients with neuropathic pain was able to induce a significant pain decrease. In agreement, we documented that the administration of topiramate and PEA was able to decrease pain symptoms in patients with nummular headache ( 15 ). Herein, we demonstrate for the first time that umPEA administration to patients with MA (1,200 mg/day for up 90 days) treated with common NSAIDs induced a significant pain relief (evaluated considering the VAS score and the number of attacks/month), irrespective to age or gender.…”

Section: Discussionsupporting

confidence: 80%

Effects of Add-On Ultramicronized N-Palmitol Ethanol Amide in Patients Suffering of Migraine With Aura: A Pilot Study

et al. 2018

Self Cite

View full text Add to dashboard Cite

Background: Palmitoyl ethanol amide (PEA) is an endogenously produced substance showing anti-nociceptive effect through both receptor and non-receptor mediated effects at the level of different cellular and tissue sites. This study showed the results of a single blind study that was conducted to evaluate both the safety and the efficacy of ultramicronized PEA (umPEA; 1,200 mg/day) for up 90 days in patients suffering of Migraine with Aura (MA) treated with NSAIDs.Methods: A total of 20 patients, 8 male (33–56-years, average 41.4 ± 7.8) and 12 female (19–61-years, average 38.5 ± 11.9) with MA were admitted to our observation and diagnosed according to ICHD-3 criteria, they received umPEA (1,200 mg/day) in combination with NSAIDs for up to 90 days. They were revaluated at 30, 60, and 90 days after treatment.Results: umPEA administration induced a statistically significant and time dependent pain relief. In particular, these effects were evident at 60 days (male P = 0.01189; female P = <0.01) and they lasted until the end of the study (male P = 0.0066; female P = 0.01473).Conclusion: Although further studies are needed, our findings indicate that in patients suffering of MA treatment with umPEA had good efficacy and safety which candidate this compound as a therapeutic tool in pain migraine management.

show abstract

Section: Discussionsupporting

confidence: 80%

Effects of Add-On Ultramicronized N-Palmitol Ethanol Amide in Patients Suffering of Migraine With Aura: A Pilot Study

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, PEA normalizes mastcell de- granulation and microglial activation thereby maintaining tissue homeostasys and therefore in a progressive decrease in endogenous production of PEA leads to an inability to regulate mastcells and microglial cells, creating pain symptoms [7,8]. Therefore um-PEA (Ultramicronized Palmithoylethanolamide) is used in those diseases in which the mechanisms of neuroinflammation are present such as neuropathies, by nerve entrapment [9] or dismetabolic [10], toxic [11] and others [12][13][14][15] and some primary headaches [16]. In this study, we used um-PEA in degenerative lumbar radiculopathies, a very frequent disorder, related to alterations involving the various structures of the lumbar spine, as vertebral body, intervertebral disc and ligament, which, at the end, cause root compression and consequently onset of pain.…”

Section: Discussionmentioning

confidence: 99%

Nonsurgical lumbar radiculopathies treated with ultramicronized palmitoylethanolamide (umPEA): A series of 100 cases

Chirchiglia

Caldarola

Signorelli

2018

Neurologia i Neurochirurgia Polska

Self Cite

View full text Add to dashboard Cite

In this clinical/observational study we have reported the administration of Palmitoylethanolamide (PEA) in patients suffering from radicular lumbar spinal pathology, who had no indication for surgical treatment. We analyzed a series of 100 cases retrospectively, all undergoing clinical and diagnostic investigations, which had shown the presence of abnormalities of the vertebral body and intervertebral discs, mainly degenerative, such as spondyloarthrosis, spondylo-discarthrosis, disc protrusion, excluding disc herniation, which fell within surgical cases. We then administered ultramicronized PEA (umPEA) to these patients, in combination with paracetamol and codeine, obtaining interesting results regarding the improvement of pain symptoms of the spine pathology, in the various checks carried out, through the administration of pain assessment scales. We also noted its safety due to the total absence of adverse effects. The obtained results encourage the use of PEA in degenerative spine pathologies.

show abstract

“…The effect of a PEA-um based FSMP in the dietary management of migraine has been initially evaluated in a clinical case of nummular migraine [ 129 ]. The patient, a 57-year-old woman suffering from superficial cranial pain since the last 10 years was administered PEA-um (600 mg/day) after a one-month treatment with topiramate (50 mg × 2/day tablet), had lead only a minor improvement on pain scales (6 on VAS, 6 on NRS, and severe pain on VRS) [ 129 ]. Two months later, a clear decrease of pain was recorded (2 on VAS, 3 on NRS, and moderate-to-mild pain on VRS) and a progressing scaling of topiramate up to 25% of the original dose was decided.…”

Section: Pre-clinical and Clinical Effects Of Pea In Micronized Anmentioning

confidence: 99%

Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries—A Systematic Review

Petrosino

Moriello

2020

IJMS

View full text Add to dashboard Cite

Neuroinflammation is a physiological response aimed at maintaining the homodynamic balance and providing the body with the fundamental resource of adaptation to endogenous and exogenous stimuli. Although the response is initiated with protective purposes, the effect may be detrimental when not regulated. The physiological control of neuroinflammation is mainly achieved via regulatory mechanisms performed by particular cells of the immune system intimately associated with or within the nervous system and named “non-neuronal cells.” In particular, mast cells (within the central nervous system and in the periphery) and microglia (at spinal and supraspinal level) are involved in this control, through a close functional relationship between them and neurons (either centrally, spinal, or peripherally located). Accordingly, neuroinflammation becomes a worsening factor in many disorders whenever the non-neuronal cell supervision is inadequate. It has been shown that the regulation of non-neuronal cells—and therefore the control of neuroinflammation—depends on the local “on demand” synthesis of the endogenous lipid amide Palmitoylethanolamide and related endocannabinoids. When the balance between synthesis and degradation of this bioactive lipid mediator is disrupted in favor of reduced synthesis and/or increased degradation, the behavior of non-neuronal cells may not be appropriately regulated and neuroinflammation exceeds the physiological boundaries. In these conditions, it has been demonstrated that the increase of endogenous Palmitoylethanolamide—either by decreasing its degradation or exogenous administration—is able to keep neuroinflammation within its physiological limits. In this review the large number of studies on the benefits derived from oral administration of micronized and highly bioavailable forms of Palmitoylethanolamide is discussed, with special reference to neuroinflammatory disorders.

show abstract

Administration of palmitoylethanolamide in combination with topiramate in the preventive treatment of nummular headache

Cited by 14 publications

References 12 publications

Effects of Add-On Ultramicronized N-Palmitol Ethanol Amide in Patients Suffering of Migraine With Aura: A Pilot Study

Effects of Add-On Ultramicronized N-Palmitol Ethanol Amide in Patients Suffering of Migraine With Aura: A Pilot Study

Nonsurgical lumbar radiculopathies treated with ultramicronized palmitoylethanolamide (umPEA): A series of 100 cases

Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries—A Systematic Review

Contact Info

Product

Resources

About